HCV相关中晚期肝癌患者DAA抗病毒治疗策略

摘要/Abstract

摘要： HCV慢性感染是导致肝癌的重要原因之一,尽管在后DAA时代根除HCV已不再困难,但对于已发展成肝癌的慢性HCV感染者,尤其是中晚期肝癌患者目前研究较少,且尚无统一的指南或共识推荐其启动DAA抗病毒治疗的具体时间。既往已有研究表明,肝癌患者使用DAA治疗可能与较低的SVR率和HCC高复发率相关,因此引发HCV相关HCC患者使用DAA治疗的争议,但亦有研究提出HCC患者经DAA治疗后可获得更长的生存期、肝癌指标改善获益。HCV相关的HCC患者是否应启动DAA治疗、启动DAA治疗的时机、DAA治疗后需注意的事项都是临床医生和患者需要关注的问题。

关键词: 丙型肝炎, 直接作用抗病毒药物, 原发性肝癌, 持续性病毒应答率, 复发

邹铭南, 蔡大川. HCV相关中晚期肝癌患者DAA抗病毒治疗策略[J]. 肝脏, 2021, 26(11): 1201-1204.

参考文献

[1] 南月敏, 高沿航, 王荣琦, 等. 原发性肝癌二级预防共识 (2021年版). 临床肝胆病杂志, 2021.29(03):216-226.
[2] Mcglynn KA, Petrick JL, HB El-Serag. Epidemiology of Hepatocellular Carcinoma. Hepatology, 2021, 73:4-13.
[3] Sinn DH, Kang D, Hong YS, et al. Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study. PLoS One, 2021, 16: e0255624.
[4] 魏来, 段钟平, 王贵强. 丙型肝炎防治指南 (2019年版). 实用肝脏病杂志, 2020, 23: 33-52.
[5] AASLD/IDSA HCV Guidance Panel, Chung RT, Davis GL, et al. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology, 2015, 62: 932-954.
[6] 国家科技部传染病防治重大专项课题《病毒性肝炎相关肝癌外科综合治疗的个体化和新策略研究》专家组. 肝细胞癌肝切除术后复发预防和治疗中国专家共识(2020版). 中国实用外科杂志, 2021,41(1):20-30.
[7] Singal AG, Lim JK, Kanwal F. AGA clinical practice update on interaction between oral direct-acting antivirals for chronic hepatitis C infection and hepatocellular carcinoma: expert review. Gastroenterology, 2019, 156: 2149-2157.
[8] AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis, 2018, 67: 1477-1492.
[9] Cabibbo G, Celsa C, Calvaruso V, et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol, 2019,71:265-273.
[10] Dang H, Yeo Y H, Yasuda S, et al. Cure with interferon-free direct-acting antiviral is associated with increased survival in patients with hepatitis C virus-related hepatocellular carcinoma from both east and west. Hepatology, 2020, 71: 1910-1922.
[11] Reig M, Mari?o Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol, 2016, 65: 719-726.
[12] Ogawa E, Nakamuta M, Furusyo N, et al. Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by DAAs. J Gastroenterol Hepatol. 2021.
[13] Singal AG, Rich NE, Mehta N, et al. Direct-Acting Antiviral Therapy not Associated with Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology. 2019, 156(6): 1683-1692. e1.
[14] Sapena V, Enea M, Torres F, et al. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut. 2021.
[15] Nakano M, Koga H, Ide T, et al. Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: a prospective multicenter cohort study. Cancer Med, 2019,8(5): 2646-2653.
[16] Yoshimasu Y, Furuichi Y, Kasai Y, et al. Predictive factors for hepatocellular carcinoma occurrence or recurrence after direct-acting antiviral agents in patients with chronic hepatitis C. J Gastrointestin Liver Dis,2019,28(1):63-71.
[17] Degasperi E, D'Ambrosio R, Iavarone M, et al. Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection. Clin Gastroenterol Hepatol,2019,17: 1183-1191.
[18] Beste L A, Green P K, Berry K, et al. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.J Hepatol, 2017, 67(1):32-39.
[19] Ogawa E, Toyoda H, Iio E, et al. Hepatitis C virus cure rates are reduced in patients with active but not inactive hepatocellular carcinoma: a practice implication. Clin Infect Dis, 2020, 71(11): 2840-2848.
[20] Chen CY, Huang CF, Cheng PN, et al. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: a real-world nationwide hepatitis C virus registry programme in Taiwan. Liver Int. 2021,41:1265-1277.
[21] Chi CT, Chen CY, Su CW, et al. Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan. J Microbiol Immunol Infect 2019,54: 385-395.
[22] Dang H, Yeo YH, Yasuda S, et al. Cure with interferon-free direct-acting antiviral is associated with increased survival in patients with hepatitis C virus-related hepatocellular carcinoma from both east and west. Hepatology,2020,71:1910-1922.
[23] Prenner SB, VanWagner LB, Flamm SL, et al. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol,2017,66 (6): 1173-1181.
[24] Konjeti VR, John BV. Interaction Between Hepatocellular Carcinoma and Hepatitis C Eradication With Direct-acting Antiviral Therapy. Curr Treat Options Gastroenterol, 2018, 16(2):203-214.
[25] Lin WC, Lin YS, Chang CW, et al. Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma. PLoS one, 2020, 15(5): e0233212.
[26] Ohki T, Satov K, Kondo M,et al. Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence. J Viral Hepat, 2021.
[27] Tani J, Senoh T, Moriya A, et al. Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study. Cancers, 2021, 13(9): 2257.
[28] Zavaglia C, Okolicsanyi S, Cesarini L, et al. Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? J Hepatol, 2017, 66(1): 236-237.
[29] Persico M, Aglitti A, Aghemo A, et al. High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. Aliment Pharmacol Ther, 2018, 47(12): 1705-1712.
[30] Reig M, Cabibbo G. Antiviral therapy in the palliative setting of HCC (BCLC B and C). J Hepatol, 2021.